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Background: Diabetic patients with positive glutamic acid decarboxylase antibody (GAD-Ab) could be classified as
autoimmune diabetes, which is discriminated into acute-onset classical type 1 diabetes (T1DM) and latent
autoimmune diabetes in adults (LADA). However, whether the decay rate of beta cell function is relevant with the
mode of onset (acute or latent-onset) is unclear. We aimed to investigate whether initial C peptide levels could
help differentiate variation of C peptide decay rate.
Methods: Five hundred and twenty-seven newly diagnosed GAD-Ab positive diabetic patients were followed up to
assess the natural course of beta cell function. Beta cell function failure was defined as fasting C peptide and
postprandial C peptide levels less than 100 pmol/L and 150 pmol/L respectively.
Results: All these diabetic patients were discriminated according to initial fasting C peptide of 300 pmol/L, that is
B+ (larger than 300 pmol/L) and B- (less than 300 pmol/L) group. The proportion of developing beta cell function
failure was 13.1% in B+ group and 90.5% in B- group, which suggested that fasting C peptide levels made a good
distinction of the heterogeneity in autoimmune diabetes. Receiver operator characteristic (ROC) analysis suggested
that the fasting C peptide level of 300 pmol/L was optimal for determining beta cell function failure with sensitivity
of 90.5% and specificity of 86.9%.
Conclusions: Initial level of fasting C peptide is a good indicator for predicting beta cell function failure in GAD-Ab
positive diabetic patients.Background
The WHO recommendation in 1999 on classification of
diabetes is now based more and more on the etiological
evidence, with autoimmunity being the most direct and
measurable evidence ever since the standardized radio-
ligand assays for islet autoantibodies have been esta -
blished [1]. So, more and more clinically diagnosed “type
2” diabetes has been re-classified as latent autoimmune
diabetes in adults (LADA), a subtype of type 1 diabetes
[2,3]. However, except for the etiology of diabetes,
clinicians are paying more attention on the progression* Correspondence: zhouzg@hotmail.com
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reproduction in any medium, provided the orof beta cell function. Evidence from UKPDS, DCCT, and
other studies has demonstrated that beta cell function
decline is closely related with the all-sides glycemic con-
trol and the diabetic complications [4]. So, to make a
distinction between the different destruction speed of
beta cell function in autoimmune diabetes is important
and LADA is specially proposed as a subtype for this
reason. According to the diagnostic definition proposed
by the Immunology of Diabetes Society (IDS), LADA is
specially referred to patients over 30 years of age, posi-
tive for at least one islet autoantibodies, and not treated
with insulin within the first 6 months after diagnosis [5].
So, the age (adult, over 30 years) and mode (latent, no
need for insulin at the initial stage) of onset are regarded
as discriminative factors for autoimmune diabetes. How-
ever, “latent” does not always “adult-onset”, and patientshis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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was also put forward because of the relative slow
progression [6].
Glutamic acid decarboxylase antibody (GAD-Ab) is
the most widely used and the most valuable autoim-
mune markers in diagnosing autoimmune diabetes,
especially for Chinese and adult-onset patients.[7,8].
Previous studies reported that GAD-Ab titer could help
identify the heterogeneity of LADA patients with
LADA-type 1 and LADA-type 2 diabetes [9,10]. But for
juvenile- and adult-onset autoimmune diabetes, the
status and the titer of GAD-Ab is not so helpful [11]. So,
to address possible predictors of the discrepancy of beta
cell loss, we have conducted a prospective study to
characterize the difference of 527 cases of autoimmune
diabetes, who have been followed closely and assessed
serum C peptide levels repeatedly. Our results indicated
that initial beta cell function was the most useful
marker for differentiating beta cell failure tendency in
autoimmune diabetes.Methods
Inclusion of subjects and data collection
This study was carried out according to the Helsinki
guidelines. All patients gave informed consent to partici-
pation in the study and the protocol was approved by
the Research Ethics Committee in Second Xiangya
Hospital, Central South University. A total of 4,469
newly diagnosed patients who were hospitalized from
July 2002 to July 2006 were screened for GAD-Ab;
five hundred and twenty-seven patients with positive
GAD-Ab were invited and agreed to participate in this
study as they fulfilled the following criteria: (1) diabetes
diagnosed according to the report of WHO in 1999; (2)
disease duration less than one year; (3) GAD-Ab positive
testing twice within one month. The disease onset was
defined as the initial diagnosis of diabetes and disease
duration was thus calculated.
All patients were treated according to the decision of
individual physician and insulin or metformin were ap-
plied in accordance with the seriousness of the case and
adjusted in line with blood glucose levels,other kinds of
hypoglycemic agents including sulfonylureas and thiazo-
lidinediones were not employed. Data from all patients,
including age of onset, diabetes duration, body mass
index (BMI), ketosis were collected. Serum was collected
for measurement of HbA1c, islet autoantibodies and C
peptide levels.
Ethics
We have complied with the recommendations of the
Declaration of Helsinki. This study was approved by the
ethics committee of Second Xiangya Hospital, CentralSouth University and informed consent was obtained
from all participants.Definition of clinical subtype of autoimmune diabetes
All these autoimmune diabetes were subdivided into two
subtypes, that is the acute-onset T1DM and latent-onset
LADA. Acute-onset autoimmune T1DM was defined by
1) Requirement of insulin therapy since diagnosis; + 2)
positive GAD-Ab. Latent-onset LADA was defined by 1)
No ketosis or ketoacidosis during the first 6 months
after diagnosis; + 2) no requirement of insulin therapy
during the first 6 months after diagnosis; + 3) positive
GAD-Ab.
Diabetes associated autoantibody analysis
Serum was analyzed for the presence of GAD-Ab by highly
sensitive and specific quantitative radioligand binding
assay methods as reported previously [12]. Intra-assay and
inter-assay coefficients of variation were 8.9% and 11.2%
(n=5) respectively. The cut-off point of GAD-Ab index
was determined according to the 99.5% upper limit of 188
healthy Chinese controls. The GAD-Ab index of 0.05 or
higher was defined as positive.
Human leukocyte antigen (HLA-DQ) genotyping
DNA was isolated from peripheral blood leukocytes using
the phenol–chloroform method [13]. The polymorphic
second exons of DQA1, DQB1 were amplified using PCR.
The HLA-DQA1 and -DQB1 types were defined by DNA
analysis using polymerase chain reaction (sequencing-
based typing). The frequencies of HLA-DQA1 and –
DQB1 genes were tested; the susceptible and protective
haplotypes were defined according to our previous report
and HLA-DQA1*03-DQB1*0303, DQA1*05-DQB1*0201
and DQA1*03-DQB1*0401 are susceptible to type 1
diabetes, and HLA- DQA1*0102-DQB1*0602 is protective
haplotypes [7].
Measurement of beta cell function
Beta cell function was assessed in all patients in two
ways: 1) fasting plasma C-peptide (FCP) concentration;
2) postprandial C-peptide (PCP): Sera were determined
2 h after a mixed meal (with about 400 cal). C-peptide
levels were measured at the time of initial inclusion
(after glucotoxicity had been removed) and during the
follow-up.
Beta cell function failure was defined as FCP and PCP
levels less than 100 pmol/L and 150 pmol/L respectively,
and the initial beta cell function was defined as preserved
(B+) if FCP level was higher than 300 pmol/L or PCP level
higher than 600 pmol/L, and those whose C peptide levels
could not meet the above criteria were defined as B-.
These cutoff values are determined according to the
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jects, type 1 and type 2 diabetic patients [14].
Statistical methods
The statistical analysis was done with SPSS 16.0 soft-
ware. Data were shown by means ± SD or as indicated.
ANOVA was used to assess differences in continuous
variables (age, age at diagnosis, HbA1c on admission,
BMI, HbA1c, C-peptide levels). When this test indicated
that there were significant differences between groups,
pair-wise comparisons were made to identify those
differences. Chi-square test was used in comparison of
classification data. All significance tests were performed
as P-value less than 0.05 and were two-tailed.
Results
Patient characteristics and different tendency of beta cell
function
Among all the 527 cases of autoimmune diabetes, the
mean age was 39.1±19.1 yr, 54.6% were males, with the
mean duration of 8.3±1.7 months,and all patients were
newly onset diabetes with duration less than one year.
One hundred and seventy-eight cases were defined as
beta cell function failure (FCP and PCP levels less than
100 pmol/L and 150 pmol/L respectively) at the begin-
ning of the study and thus were not followed up. Forty-
nine patients descended to beta cell failure when
followed up for 12 months and 24 failure patients atTable 1 Clinical features in patients with distinct variation of
Group 1: Patients with beta cell









Ketosis (%) 81.5% 68.3%
HbA1c 11.0±3.4 10.7±3.5
FCP (pmol/L) 25.2(0–99.0) 202.3(102.3–154















8/178 (4.5%) 6/104 (5.8%)
Note: Compared with patients who had beta cell function failure (group 1 + group
age of onset, less frequency of kenosis-prone diabetes, lower titer of GAD-Ab, and h
clinical features of group 1 and group 2 were similar in onset age, ketosis tendency
groups. When compared with group 1, #P<0.05.k.24 months, 14 at 36 months, 17 at 48 months.
Altogether, 104 patients developed beta cell function
failure during the 48 months’ follow up.
Difference of beta cell function failure in acute-and
latent-onset autoimmune diabetic patients
We tested whether patients in T1DM and LADA had
disparate progression of beta cell function. Among all
the 258 T1DM cases, 216 patients developed beta cell
failure at the onset or during follow-up of the study,
with the proportion of 83.7%; while for LADA patients,
24.5% developed beta cell failure at the onset or during
follow-up of the study.
Different clinical features in patients with distinct
variation of beta cell function
All the autoimmune diabetic patients were divided into
three subgroups according to their distinct outcomes of
beta cell function, patients with beta cell function failure
at the onset of the disease (group 1); patients who
developed beta cell function failure during the follow-up
(group 2); patients who did not develop beta cell
function failure during the follow-up (group 3). The
clinical features of three subgroups were listed in Table 1.
Patients in group 1 had the highest frequency of HLA-
DQ susceptible haplotypes, while the most frequency of
protective haplotypes was found in group 3, which
suggested the HLA-DQ gene susceptibility present abeta cell function
nts who developed beta
ilure during the follow-up
Group 3: Patients who did not
develop beta cell function failure












2), patients in group 3 who did not develop beta cell function failure had later
igher FCP levels. When compared with group 1 and group 2, * P<0.05. The
, HbA1c level, however, the serum FCP levels were significantly different in two
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function. Compared with patients who had beta cell
function failure (group 1 + group 2), those who did not
develop beta cell function failure had later age of onset,
less frequency of kenosis-prone diabetes, lower titer of
GAD-Ab, and higher FCP levels. The clinical features
of those who had beta cell failure at the onset stage
and patients who developed beta cell function failure
later were similar in onset age, ketosis tendency, HbA1c
level, however, the serum FCP levels were significantly
different in two groups.
Factors which influence the decline of beta cell function
To evaluate the possible risk factors contributing to the
development of beta cell failure, multivariate analysis and
a Cox regression analysis was performed (age of onset,
diabetes duration, frequency of ketosis, BMI, initial fasting
C peptide, GAD-Ab titer, HLA-DQ haplotypes were
analyzed as inclusive factors). Multivariate analysis showed
that age of onset, the frequency of ketosis, BMI and FCP
levels were significantly correlated with distinct outcomes
of beta cell function. Subsequently, the results of Cox re-
gression analysis revealed that influencing factor included
FCP levels, age of onset and BMI, with the largest coeffi-
cient of determination (0.89) for initial FCP levels.
The natural tendency of C peptide levels during the
follow-up was shown in Figure 1. The fasting C peptide
levels in other two groups with different ending of beta
cell function were dramatically different (178 patients
with beta cell failure were not followed up). The above
results suggested that initial FCP levels were closely
related with the prognosis of beta cell function in
autoimmune diabetes.
Re-classification of autoimmune diabetes with initial beta
cell function
The above results suggested that initial FCP levels
maybe the promising predictor of possible beta cellFigure 1 Changes of fasting C peptide in different autoimmune diabe
fasting C peptide (FCP) in different autoimmune diabetic patients with dist
dramatic discrimination in the C peptide decay rate.function failure. We arbitrarily defined better preserva-
tion of beta cell function (B+) when the FCP levels were
more than 300 pmol/L and worse beta cell function (B-)
when FCP were less than 300 pmol/L. Follow-up study
showed that a dramatic difference of beta cell function
was found, 13.1% in B+ group while 90.5% in B- group
progressed to beta cell function failure. Considering the
proportion of 83.7% in T1DM and 24.5% in LADA
progressed to beta cell failure, the results showed that
initial serum FCP level made a better distinction of the
heterogeneity in autoimmune diabetes than WHO
recommendation with LADA sub-typing.
We then tested the optimal FCP levels in defining
better or worse beta cell function preservation. ROC
analysis found that the FCP level of 300 pmol/L was op-
timal (Figure 2), with sensitivity of 90.5% and specificity
of 86.9% for determining beta cell function failure. The
sensitivity and specificity of FCP level of 200 pmol/L
and 400 pmol/L were 96.3%, 80.7%, 78.6% and 87.9%
respectively.
Discussion
Islet beta cell function plays an important role in the
pathogenesis of diabetes mellitus, and the destiny of beta
cell function failure leads to the uncontrollable hypergly-
cemia in long term and diabetic complications. From the
patients’ point of view, it is of highest priority to find
factors for the discrimination of beta cell function
course. For autoimmune diabetes, beta cell function
failure is more apparent as the immunity mediated beta
cell destruction [15]. However, the heterogeneous tempo
of beta cell function failure in autoimmune diabetes was
recognized and LADA is subdivided specially [16,17].
However, the arbitrary classification scheme using onset
age to categorize the heterogeneity of autoimmune
diabetes has some limitations; 1) the confirmation of the
exact onset age is not so certain, 2) the onset age is a
continuous parameter, the optimal cut off point istic patients with distinct endings of beta cell function. Changes of
inct endings of beta cell function were shown, and FCP made a
Figure 2 Receiver operating curve analysis of fasting C peptide in differentiating beta cell function in autoimmune diabetes. The
differentiating diagnostic value of fasting C peptide (FCP) in autoimmune diabetes was shown in the receiver operating curve (ROC). The top left
corner of the curve represented the optimal FCP cur-off point, which was at the level of 300 pmol/L.
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be reflected by the “late onset” [19], classical type 1
diabetes in adults is common, and “young onset” could
also be “latent”.
So, we aimed to investigate whether initial C peptide
levels is useful marker for differentiating variation of C
peptide decay rate. There were three different outcomes
of beta cell function progression, that is, beta cell func-
tion failure at the onset of the disease, failure during the
follow-up and no failure during the follow-up, and initial
fasting C peptide levels was dramatically different in
patients with distinct progressive endings of beta cell
function. So, we proposed that the disparate outcomes
of beta cell function in autoimmune diabetes could be
better discriminated by initial FCP levels. When defined
beta cell function as B+ or B- by FCP level of 300 pmol/L,
we found 13.1% in B+ group while 90.5% in B- group
progressed to beta cell function failure. So, initial FCP
levels made a better distinction of the heterogeneity in
autoimmune diabetes with the sensitivity of 90.5% and
specificity of 86.9%.
Positive islet autoantibodies in autoimmune diabetes
patients are thought to indicate a progressive autoimmune disease in the beta cells associated with a gradual
decrease in insulin secretion. So, islet autoantibodies (A)
was applied as one marker to dissect the heterogeneity
of ketosis prone diabetes by Maldonado et al., beta cell
function (B) was also used, and four different combi-
nation of AB groups with diverse clinical features were
found. Therefore, the classification scheme using A
(autoantibody) and B (beta cell function) was proposed
in discriminating ketosis-prone diabetes [20].
For antibody positive autoimmune diabetes, it is likely
that the beta cell destruction continues after diagnosis,
with varying rate until the beta cells are depleted [21,22].
C-peptide levels at diagnosis, age, gender, titer of GAD-Ab,
degree of obesity and puberty, and levels of HbA1c are
factors reported to influence beta cell function after diag-
nosis [23]. In our study, we found that initial beta cell
function reflected by fasting C peptide levels might be a
good marker for dissection the heterogeneity of auto-
immune diabetes. The possible reasons are, 1) the value of
FCP levels had a higher sensitivity and specificity in
predicting beta cell failure; 2) initial C peptide levels could
be a mixed reflection of age onset, predisposing genes,
the extent of insulin resistance and insulin deficiency.
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for three years, and determined beta-cell function with
early insulin vs conventional treatment, and found
only baseline level of C-peptide significantly influenced
C-peptide level after 3 years [24]. Other study reported
that initial C-peptide is a predicting factor for effectiveness
of insulin intervention for LADA [25]. For GAD-Ab posi-
tive LADA patients (without classical type 1 diabetes), the
same trend of C-peptide declining curve in patients with
different initial C-peptide levels, as shown in our Figure 1,
had been also reported [26]. So, the use of initial beta cell
function may have important implications in predicting
the prognosis of autoimmune diabetes.
Conclusions
Based on this study, we conclude that initial level of
fasting C peptide, instead of age and mode of onset, is a
better criterion for predicting beta cell function failure
in GAD-Ab positive autoimmune diabetes.
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